Castle Biosciences, Inc., a health care company headquartered in Friendswood, United States, specializes in providing imaging services for the diagnostic and prognostic testing of cancers. The company also engages in research and development activities, serving customers nationwide. Its stock is traded on the Nasdaq, and it can be accessed through its website at www.castlebiosciences.com .
As of January 14, 2026, Castle Biosciences reported a closing stock price of $40.75. This price is nearing the company’s 52-week high of $42.175, achieved on December 21, 2025. Conversely, the stock’s 52-week low was recorded at $14.59 on August 3, 2025. The recent price movement suggests moderate upside potential within the stock’s 52-week range.
The company’s market capitalization stands at approximately $1.19 billion USD. Despite the positive trajectory in stock price, Castle Biosciences faces significant profitability challenges, as indicated by its negative price-to-earnings ratio of -93.23. This suggests that the company is currently operating at a loss. In contrast, the price-to-book ratio of 2.46 indicates that the stock is valued at roughly 2½ times the book value per share.
For the fiscal year 2025, Castle Biosciences projects its revenue to surpass $340 million. This projection underscores the company’s growth potential despite the current profitability issues. The combination of a strong market cap and projected revenue growth highlights the company’s strategic positioning within the health care sector, particularly in the niche of cancer diagnostic and prognostic imaging services.
